Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Adimab LLC (Adimab) is an antibody discovery technology provider that provides antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic disease, infectious disease, and others. Its platform delivers and optimizes various panels of therapeutically relevant antibodies that meet the standards for affinity, epitope coverage, species cross reactivity and developability. The company has completed discovery programs in various protein classes such as serum proteins, TNF superfamily receptors, ECM adhesion receptors, enzymes, natural peptides, cytokines, ion channels and GPCRs, among others. Adimab is headquartered in Lebanon, New Hampshire, the US.

Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Adimab Raises US$13.8 Million In Series F Financing 12
Partnerships 14
Adimab Enters into Agreement with Boehringer Ingelheim 14
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Licensing Agreements 35
Eli Lilly Enters into Licensing Agreement with Adimab 35
Arsanis Enters into Licensing Agreement with Adimab 36
Kite Pharma Exercises Option for Licensing Agreement with Adimab 37
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38
Adimab Enters into Licensing Agreement with Merck 39
Adimab Enters Into Licensing Agreement With Novo Nordisk 40
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab LLC - Key Competitors 44
Adimab LLC - Key Employees 45
Adimab LLC - Locations And Subsidiaries 46
Head Office 46
Recent Developments 47
Other Significant Developments 47
Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 47
Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 49
Jan 08, 2018: Adimab Provides Year-End Update on 2017 Partnership Activities 50
Jan 10, 2017: Adimab Provides Annual Update on 2016 Partnerships and Milestones 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List Of Tables


Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adimab LLC, Deals By Therapy Area, 2012 to YTD 2018 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adimab Raises US$13.8 Million In Series F Financing 12
Adimab Enters into Agreement with Boehringer Ingelheim 14
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Eli Lilly Enters into Licensing Agreement with Adimab 35
Arsanis Enters into Licensing Agreement with Adimab 36
Kite Pharma Exercises Option for Licensing Agreement with Adimab 37
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38
Adimab Enters into Licensing Agreement with Merck 39
Adimab Enters Into Licensing Agreement With Novo Nordisk 40
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab LLC, Key Competitors 44
Adimab LLC, Key Employees 45

List Of Figures


Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adimab LLC - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Adimab LLC (Adimab) is an antibody discovery technology provider that provides antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience

USD 250 View Report

Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Adimab LLC (Adimab) is an antibody discovery technology provider that offers antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience

USD 250 View Report

IXYS LLC - Strategic SWOT Analysis Review

IXYS LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on

USD 125 View Report

Prometheon Pharma LLC - Product Pipeline Analysis, 2019 Update

Prometheon Pharma LLC - Product Pipeline Analysis, 2019 Update market research report available in single user pdf license with Aarkstore Enterprise at USD 750

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available